Metastatic colorectal cancer has an average overall survival of three years. With limited treatment options as standard of care or effective targetable mutations, ESMO23 shined, providing answers to unanswered questions and a potentially brighter future for this cancer. Concerningly, we are seeing higher rates of colorectal cancer in lower and middle-income countries and those under the age of 50. We explore sotorasib in KRASG12C mutated cancers with panitumumab, the use of aspirin to reduce the risk of cancer recurrence and whether triplet therapy is better than double in potentially resectable colorectal cancer.
Studies discussed in today's episode (subscription may be required)
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}